Ruxolitinib
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Mechanism
Blocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cells
Development stage
Phase I/II
Evidence level
Level 2 (Repositioning)
Developer
Incyte / Multiple
Overview
FDA-approved for GVHD. Blocks JAK1/2 downstream of SASP. Seno-morphic approach. Generic available.
Ruxolitinib clinical trials
Explore related
Medical disclaimer. This page summarizes research about Ruxolitinib for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.